The new state-of-the-art facility in Plainville, Massachusetts will be manufacturing materials central to production of gene-based therapeutics.
Thermo Fisher Scientific has expanded its cell and gene therapy capabilities with the opening of its new viral vector manufacturing facility in Massachusetts. The 300,000 square foot site will add approximately 300 jobs to support the development, testing and manufacture of viral vectors, which are critical components in the development and commercialisation of gene therapies.
“Plainville is an impressive addition to our pharma services network as we continue to invest and innovate cell and gene therapy services, products and workflows,” said Marc N Casper, Chairman, President and CEO of Thermo Fisher Scientific. “We are enabling our customers to speed their scientific discoveries in cell and gene therapy while also supporting their manufacturing needs, whether they are early in the development process or ready to transition to clinical or commercial scale.”
The new cGMP-compliant Plainville facility significantly expands the company’s clinical and commercial viral vector capacity to six sites in the USA and Europe. The site features sustainable construction design, flexible laboratory and production suites, adjacent warehousing, and office space, as well as Thermo Fisher’s advanced bioproduction and analytical instrumentation technologies.
The new Plainville facility is part of an investment strategy to provide customers with fully integrated capabilities that connect the entire cell and gene therapy value chain - from early development and clinical scale-up to commercial manufacturing. These include translational sciences labs for early-stage development; plasmid DNA manufacturing; viral vector services; cell therapy manufacturing; and, integrated commercial packaging and distribution services. With over 20 years of experience in cGMP viral vector manufacturing, the company has produced more than 130 viral vector products used to develop treatments for cancer, blood disorders and other genetic diseases.
In addition, the new Patheon Quick to Clinic viral vector is an all-inclusive manufacturing platform utilising optimised, Investigational New Drug-ready processes for lentivirus and adeno-associated virus manufacturing to allow rapid process development, de-risk regulatory pathway and accelerates timeline from discovery to clinic.
